BIONOTE, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,175 KRW | -0.83% |
|
-1.18% | -1.65% |
| 2023 | BioNote, Inc.(KOSE:A377740) added to S&P Global BMI Index | CI |
| 2023 | SD Biosensor, Inc announced that it has received KRW 226.0893359 billion in funding from BioNote, Inc. | CI |
Valuation
| Fiscal Period: December | 2022 | 2023 |
|---|---|---|
| Capitalization 1 | 874,096 | 433,228 |
| Enterprise Value (EV) 1 | 153,997 | 37,988 |
| P/E ratio | 2.63 x | -21.1 x |
| Yield | 5.71% | 4.71% |
| Capitalization / Revenue | 1.82 x | 4.81 x |
| EV / Revenue | 0.32 x | 0.42 x |
| EV / EBITDA | 0.51 x | -0.98 x |
| EV / FCF | 1.18 x | -2.03 x |
| FCF Yield | 84.4% | -49.2% |
| Price to Book | 0.55 x | 0.28 x |
| Nbr of stocks (in thousands) | 101,876 | 102,056 |
| Reference price 2 | 8,580 | 4,245 |
| Announcement Date | 3/21/23 | 3/20/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 |
|---|---|---|
| Net sales 1 | 479,657 | 90,081 |
| EBITDA 1 | 301,861 | -38,962 |
| EBIT 1 | 295,410 | -47,168 |
| Operating Margin | 61.59% | -52.36% |
| Earnings before Tax (EBT) 1 | 414,778 | -109,491 |
| Net income 1 | 307,798 | -20,497 |
| Net margin | 64.17% | -22.75% |
| EPS 2 | 3,264 | -201.0 |
| Free Cash Flow 1 | 129,964 | -18,697 |
| FCF margin | 27.1% | -20.76% |
| FCF Conversion (EBITDA) | 43.05% | - |
| FCF Conversion (Net income) | 42.22% | - |
| Dividend per Share 2 | 490.0 | 200.0 |
| Announcement Date | 3/21/23 | 3/20/24 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 |
|---|---|---|
| Net Debt 1 | - | - |
| Net Cash position 1 | 720,100 | 395,240 |
| Leverage (Debt/EBITDA) | - | - |
| Free Cash Flow 1 | 129,964 | -18,697 |
| ROE (net income / shareholders' equity) | 21.4% | -1.3% |
| ROA (Net income/ Total Assets) | 11.4% | -1.76% |
| Assets 1 | 2,705,605 | 1,164,575 |
| Book Value Per Share 2 | 15,707 | 15,252 |
| Cash Flow per Share 2 | 6,685 | 1,444 |
| Capex 1 | 42,266 | 3,963 |
| Capex / Sales | 8.81% | 4.4% |
| Announcement Date | 3/21/23 | 3/20/24 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -1.65% | 312M | |
| -5.56% | 181B | |
| -0.11% | 108B | |
| -6.17% | 66.12B | |
| +2.64% | 50.65B | |
| +6.58% | 43.11B | |
| +4.91% | 41.3B | |
| +21.98% | 31.6B | |
| +14.45% | 25.03B | |
| -5.81% | 24.16B |
- Stock Market
- Equities
- A377740 Stock
- Financials BioNote, Inc.
